[HTML][HTML] Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum
A Tuekprakhon, R Nutalai, A Dijokaite-Guraliuc… - Cell, 2022 - cell.com
The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …
[HTML][HTML] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone
progressive change, with variants conferring advantage rapidly becoming dominant …
progressive change, with variants conferring advantage rapidly becoming dominant …
[HTML][HTML] A delicate balance between antibody evasion and ACE2 affinity for Omicron BA. 2.75
Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused
successive global waves of infection. These variants, with multiple mutations in the spike …
successive global waves of infection. These variants, with multiple mutations in the spike …
The role of pseudotype neutralization assays in understanding SARS CoV-2
D Cantoni, M Mayora-Neto… - Oxford open …, 2021 - academic.oup.com
Neutralization assays are crucial tools to quantify the presence of functional neutralizing
antibodies in serum samples. Since the SARS-CoV-2 virus (the causative agent of COVID …
antibodies in serum samples. Since the SARS-CoV-2 virus (the causative agent of COVID …
[HTML][HTML] A structure-function analysis shows SARS-CoV-2 BA. 2.86 balances antibody escape and ACE2 affinity
Summary BA. 2.86, a recently described sublineage of SARS-CoV-2 Omicron, contains
many mutations in the spike gene. It appears to have originated from BA. 2 and is distinct …
many mutations in the spike gene. It appears to have originated from BA. 2 and is distinct …
[HTML][HTML] Coronavirus pseudotypes for all circulating human coronaviruses for quantification of cross-neutralizing antibody responses
The novel coronavirus SARS-CoV-2 is the seventh identified human coronavirus.
Understanding the extent of pre-existing immunity induced by seropositivity to endemic …
Understanding the extent of pre-existing immunity induced by seropositivity to endemic …
[HTML][HTML] Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK
As of June, 2021, the UK population is only partly vaccinated against COVID-19, with many
people having received just one vaccination dose (either BNT162b2 [Pfizer–BioNTech]) or …
people having received just one vaccination dose (either BNT162b2 [Pfizer–BioNTech]) or …
[HTML][HTML] Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis
MJ Ruiz, G Siracusano… - Frontiers in …, 2022 - frontiersin.org
The role of the mucosal pulmonary antibody response in coronavirus disease 2019 (COVID-
19) outcome remains unclear. Here, we found that in bronchoalveolar lavage (BAL) samples …
19) outcome remains unclear. Here, we found that in bronchoalveolar lavage (BAL) samples …
[HTML][HTML] Antigenic characterization of SARS-CoV-2 Omicron subvariant BA. 4.6
A Dijokaite-Guraliuc, R Das, R Nutalai, D Zhou… - Cell Discovery, 2022 - nature.com
Dear Editor, Since the emergence of the Omicron BA. 1.1. 529 variant of SARS-CoV-2 in
November 2021 1, a number of Omicron sublineages with increased antibody evasion …
November 2021 1, a number of Omicron sublineages with increased antibody evasion …
[HTML][HTML] Comparison of serological assays for the detection of SARS-CoV-2 antibodies
SARS-CoV-2 virus was first detected in late 2019 and circulated globally, causing COVID-
19, which is characterised by sub-clinical to severe disease in humans. Here, we investigate …
19, which is characterised by sub-clinical to severe disease in humans. Here, we investigate …